Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study.
BACKGROUND Obesity-related heart failure with preserved ejection fraction (HFpEF) is characterized by concentric remodeling, diastolic dysfunction, and systemic inflammation. Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial weight loss, but real-world echocardiographic evidence of cardiac reverse re...